Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Urbano Anido-Herranz"'
Autor:
Urbano Anido-Herranz, Ovidio Fernandez-Calvo, Juan Ruiz-Bañobre, Sara Martinez-Breijo, Natalia Fernandez-Nuñez, Zulema Nogareda-Seoane, Miguel Garrido-Pumar, Javier Casas-Nebra, Gloria Muñiz-Garcia, Paula Portela-Pereira, Antonio Gomez-Caamaño, Daniel Adolfo Perez-Fentes, Lucia Santome-Couto, Martín Lázaro, Aurea Molina-Diaz, Ana Medina-Colmenero, Sergio Vazquez-Estevez
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionRadium-223 dichloride (Ra-223) is recommended as a treatment option for metastatic castration-resistant prostate cancer (mCRPC) patients with symptomatic bone metastases and no visceral disease, after docetaxel failure, or in patients who
Externí odkaz:
https://doaj.org/article/54152fa9facb47b9970ec092bda4d1a6
Autor:
Yoel Z. Betancor, Miriam Ferreiro-Pantín, Urbano Anido-Herranz, Mar Fuentes-Losada, Luis León-Mateos, Silvia Margarita García-Acuña, Vanessa Vaamonde-Rodríguez, Beatriz García-Pinel, Víctor Cebey-López, Rosa Villaverde-Viaño, Helena Lombardía-Rodríguez, Martin Kotrulev, Natalia Fernández-Díaz, Iria Gomez-Tourino, Carlos Fernández-Baltar, Jorge García-González, Jose M. C. Tubio, Rafael López-López, Juan Ruiz-Bañobre
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
In the advanced renal cell carcinoma (RCC) scenario, there are no consistent biomarkers to predict the clinical benefit patients derived from immune checkpoint blockade (ICB). Taking this into consideration, herein, we conducted a retrospective study
Externí odkaz:
https://doaj.org/article/3df50f215da44f60a777ca651a4ba236
Autor:
Urbano Anido Herranz
Publikováno v:
Cancer Medicine, Vol 11, Iss S1, Pp 47-53 (2022)
Abstract Thyroid cancer is the most frequent endocrine tumor. However, in locally advanced or metastatic disease we have only two types of treatment at our disposal: radioactive iodine (RAI) when the disease is RAI‐sensitive and multikinase inhibit
Externí odkaz:
https://doaj.org/article/ea4da9504a3b4c5a801b708b725ab9ff
Autor:
Bernadett Szabados, Mark Kockx, Zoe June Assaf, Pieter-Jan van Dam, Alejo Rodriguez-Vida, Ignacio Duran, Simon J. Crabb, Michiel S. Van Der Heijden, Albert Font Pous, Gwenaelle Gravis, Urbano Anido Herranz, Andrew Protheroe, Alain Ravaud, Denis Maillet, Maria Jose Mendez, Cristina Suarez, Mark Linch, Aaron Prendergast, Charlotte Tyson, Diana Stanoeva, Sofie Daelemans, Miche Rombouts, Sanjeev Mariathasan, Joy S. Tea, Kelly Mousa, Shruti Sharma, Alexey Aleshin, Romain Banchereau, Daniel Castellano, Thomas Powles
Publikováno v:
European urology
[Background] Neoadjuvant immunotherapies hold promise in muscle-invasive bladder cancer (MIBC).
[Objective] To report on 2-yr disease-free (DFS) and overall (OS) survival including novel tissue-based biomarkers and circulating tumor DNA (ctDNA)
[Objective] To report on 2-yr disease-free (DFS) and overall (OS) survival including novel tissue-based biomarkers and circulating tumor DNA (ctDNA)
Autor:
Miriam Ferreiro-Pantín, Urbano Anido-Herranz, Yoel Z. Betancor, Víctor Cebey-López, Luis León-Mateos, Jorge García-González, Silvia Margarita García-Acuña, Natalia Fernández-Díaz, Jose M. C. Tubio, Rafael López-López, Juan Ruiz-Bañobre
BackgroundIn the advanced urothelial carcinoma (aUC) scenario there are no consistent biomarkers to predict the benefit patients derived from immune checkpoint blockade. Recently a novel pan-tumor molecular tissue-based biomarker, the Immunotherapy R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc006b59288a791da1e8eedd00fe6d41
https://doi.org/10.1101/2023.04.11.23288423
https://doi.org/10.1101/2023.04.11.23288423
Autor:
Alberto Carretero-González, David Lora, Isabel Martín Sobrino, Irene Sáez Sanz, María T. Bourlon, Urbano Anido Herranz, Nieves Martínez Chanzá, Daniel Castellano, Guillermo de Velasco
Publikováno v:
Cancers, Vol 12, Iss 7, p 1945 (2020)
Immune checkpoint inhibitors (ICIs) are soluble antibodies that have dramatically changed the outcomes including overall survival in a subset of kidney tumors, specifically in renal cell carcinoma (RCC). To date, there is no a single predictive bioma
Externí odkaz:
https://doaj.org/article/3b34b3ca19814b6690f4f94cd6c715db
Autor:
Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, Nobuaki Matsubara, Lajos Géczi, Susanna Y-S Cheng, Yves Fradet, Stephane Oudard, Christof Vulsteke, Rafael Morales Barrera, Aude Fléchon, Seyda Gunduz, Yohann Loriot, Alejo Rodriguez-Vida, Ronac Mamtani, Evan Y Yu, Kijoeng Nam, Kentaro Imai, Blanca Homet Moreno, Ajjai Alva, Diana Vera Cascallar, Mirta Varela, Mauricio Fernandez Lazzaro, Diego Lucas Kaen, Gabriela Gatica, David Hugo Flores, Agustin Falco, Matias Molina, Filip Van Aelst, Brieuc Sautois, Jean-Pascal Machiels, Denis Schallier, Leandro Brust, Liane Rapatoni, Sergio J Azevedo, Gisele Marinho, Joao Paulo Holanda Soares, Carlos Dzik, Jamile Almeida Silva, Andre Poisl Fay, Joel Gingerich, Cristiano Ferrario, Kylea Potvin, Marie Vanhuyse, Mahmoud Abdelsalam, Susanna Cheng, Christian Caglevic, Felipe Reyes, Jose Luis Leal, Francisco Francisco, Carolina Ibanez, Florence Joly, Brigitte Laguerre, Sylvain Ladoire, Aude Flechon, Delphine Topart, Olivier Huillard, Stéphane Oudard, Marine Gross-Goupil, Stephane Culine, Gwenaelle Gravis, Peter Reichardt, Margitta Retz, Jan Herden, David Pfister, Carsten Ohlman, Michael Stoeckle, Manfred Wirth, Anja Lorch, Guenter Niegisch, Peter J Goebell, Martin Boegemann, Axel Merseburger, Georgios Gakis, Jens Bedke, Andreas Neisius, Christian Thomas, Thomas Hoefner, Andras Telekes, Judit Erzsebet Kosa, Janos Revesz, Gyorgy Bodoky, Tibor Csoszi, Andras Csejtei, Lajos Geczi, Agnes Ruzsa, Zsuzsanna Kolonics, Jozsef Erfan, Ray McDermott, Richard Bambury, Avishay Sella, Stephen Jay Frank, Daniel Kejzman, Olesya Goldman, Eli Rosenbaum, Avivit Peer, Raanan Berger, Keren Rouvinov, David Sarid, Satoshi Fukasawa, Gaku Arai, Akito Yamaguchi, Akira Yokomizo, Tatsuya Takayama, Hidefumi Kinoshita, Eiji Kikuchi, Ryuichi Mizuno, Yasuhisa Fujii, Naoto Sassa, Yoshihisa Matsukawa, Kiyohide Fujimoto, Toshiki Tanikawa, Yoshihiko Tomita, Kazuo Nishimura, Masao Tsujihata, Masafumi Oyama, Naoya Masumori, Hiroomi Kanayama, Toshimi Takano, Yuji Miura, Jun Miyazaki, Akira Joraku, Tomokazu Kimura, Yoshiaki Yamamoto, Kazuki Kobayashi, Ronald De Wit, Maureen Aarts, Winald Gerritsen, Maartje Los, Laurens Beerepoot, Adel Izmailov, Sergey Igorevich Gorelov, Boris Yakovlevich Alekseev, Andrey Semenov, Vladimir Anatolyevich Kostorov, Sergey M Alekseev, Alexander Zyryanov, Vasiliy Nikolaevich Oschepkov, Vladimir Aleksandrovich Shidin, Vladimir Ivanovich Vladimirov, Rustem Airatovich Gafanov, Petr Alexandrovich Karlov, David Brian Anderson, Lucinda Shepherd, Graham Lawrence Cohen, Bernardo Louis Rapoport, Paul Ruff, Nari Lee, Woo Kyun Bae, Hyo Jin Lee, Urbano Anido Herranz, Enrique Grande, Teresa Alonso Gordoa, Josep Guma Padro, Daniel Castellano Gauna, Jose Angel Arranz, Jose Munoz Langa, Regina Girones Sarrio, Alvaro Montesa Pino, Maria Jose Juan Fita, Yu-Li Su, Yung-Chang Lin, Wen-Pin Su, Ying-Chun Shen, Yen-Hwa Chang, Yi-Hsiu Huang, Virote Sriuranpong, Phichai Chansriwong, Vichien Srimuninnimit, Pongwut Danchaivijitr, Huseyin Abali, Sinan Yavuz, Ozgur Ozyilkan, Mehmet Ali Nahit Sendur, Meltem Ekenel, Mustafa Ozguroglu, Cagatay Arslan, Mustafa Ozdogan, Alison Birtle, Robert Huddart, Maria de Santis, Anjali Zarkar, Linda Evans, Syed Hussain, Christopher DiSimone, Antonio F Muina, Peter Schlegel, Haresh S Jhangiani, Michael Harrison, Dennis E Slater, David Wright, Ivor J Percent, Jianqing Lin, Clara Hwang, Sumati Gupta, Madhuri Bajaj, Robert Galamaga, John Eklund, James Wallace, Mikhail Shtivelband, Jason Jung-Gon Suh, Nafisa Burhani, Matthew Eadens, Krishna Gunturu, Earle Burgess, John Wong, Arvind Chaudhry, Peter Van Veldhuizen, Stephanie Graff, Christian A Thomas, Ian D Schnadig, Benedito Carneiro, Maha Hussain, Alicia Morgans, John T Fitzharris, Ira A Oliff, Jacqueline Vuky, Ralph Hauke, Ari Baron, Monika Joshi, Britt H Bolemon, Peter Jiang, Anthony E Mega, Maurice Markus, Nicklas Pfanzelter, William Eyre Lawler, Patrick Wayne Cobb, Jay G Courtright, Sharad Jain, Gurjyot Doshi, Vijay K Gunuganti, Oliver Alton Sartor, Scott W Cole, Hani Babiker, Edward M Uchio, Alexandra Drakaki, Heather D Mannuel, Elizabeth Guancial, Chunkit Fung, Anthony Charles, Robert J Amato, Yull Arriaga, Isaac Bowman, Steven Ades, Robert Dreicer, Evan Yu, David I Quinn, Mark Fleming
Publikováno v:
The lancet oncology
The Lancet. Oncology, Vol. 22, no. 7, p. 931-945 (2021)
The Lancet. Oncology, Vol. 22, no. 7, p. 931-945 (2021)
Summary Background PD-1 and PD-L1 inhibitors are active in metastatic urothelial carcinoma, but positive randomised data supporting their use as a first-line treatment are lacking. In this study we assessed outcomes with first-line pembrolizumab alon
Autor:
Begoña Taboada, Valladares, Patricia Calvo, Crespo, Urbano Anido, Herranz, Antonio Gómez, Caamaño
Publikováno v:
Journal of Clinical and Translational Research
Background: Adjuvant treatment for both small-cell and non-small-cell lung cancer is a controversial topic. There are no published results from prospective studies that either confirm or reject the benefit of adjuvant radiotherapy, although the prese
Autor:
Vanesa Varela Pose, María Patricia Fierro Alanis, Anaberta Bermudez Naveira, Oskarina Lourdes Silva Gonzalez, Jorge Fernandez Noya, Urbano Anido Herranz, Rafael Lopez Lopez
Publikováno v:
Case Reports in Oncological Medicine, Vol 2017 (2017)
Superior cava venous obstruction use to show a typical clinical presentation and a CT scan or even an ultrasonography can be sufficient to achieve an accurate diagnosis, but in this case, to obtain the final diagnosis, a multimodal assessment is need
Externí odkaz:
https://doaj.org/article/15ba3dbdeef04473bc1601ebd352e583
Autor:
Urbano Anido Herranz, Ovidio Fernandez Calvo, Sara Martinez Breijo, Natalia Fernández Núñez, Zulema Nogareda Seoane, Miguel Garrido Pumar, Javier Casas, Gloria Muñiz Garcia, Paula Portela Pereira, Antonio Gomez Caamaño, Daniel Pérez Fentes, Lucía Santomé, Gerardo Huidobro Vence, Aurea Molina Díaz, Ana Medina, Juan Ruiz Bañobre, Sergio Vázquez Estévez
Publikováno v:
Journal of Clinical Oncology. 41:96-96
96 Background: Radium-223 represents an option for symptomatic metastatic castration-resistant prostate cancer (mCRPC) after demonstrated an overall survival improvement in the ALSYMPCA trial. Radium-223 real-life experiences are scarce, particularly